Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.
Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.
复制标题
DOI：
10.18926/amo/32888
复制
发表时间：
2007-04
影响因子：
0.5
通讯作者：
T. Yasuhara;T. Shingo;I. Date
中科院分区：
文献类型：
--
作者：
T. Yasuhara;T. Shingo;I. Date
许多使用动物的研究表明，神经胶质细胞源性神经营养因子（GDNF）对多巴胺能神经元具有强大的神经保护和神经恢复作用。尽管 2006 年发表的 GDNF 治疗随机对照试验结果为阴性，但关于治疗的有效性和安全性仍存在争议，但几项试点研究阐明了持续壳内 GDNF 输注对帕金森病 (PD) 患者的有效性。十年来，我们的实验室一直在动物身上研究GDNF的功效和最合适的给药方法，因此我们获得了一些与临床试验结果相对应的可靠数据。在这篇综述中，我们概述了我们的研究和与 GDNF 相关的其他关键研究、研究现状、需要克服的问题以及未来使用 GDNF 治疗 PD 的预测。
Many studies using animals clarify that glial cell line-derived neurotrophic factor (GDNF) has strong neuroprotective and neurorestorative effects on dopaminergic neurons. Several pilot studies clarified the validity of continuous intraputaminal GDNF infusion to patients with Parkinson's disease (PD), although a randomized controlled trial of GDNF therapy published in 2006 resulted in negative outcomes, and controversy remains about the efficacy and safety of the treatment. For a decade, our laboratory has investigated the efficacy and the most appropriate method of GDNF administration using animals, and consequently we have obtained some solid data that correspond to the results of clinical trials. In this review, we present an outline of our studies and other key studies related to GDNF, the current state of the research, problems to be overcome, and predictions regarding the use of GDNF therapy for PD in the future.